←
Terray Therapeutics43 posts
Terray Therapeutics avatar

Terray Therapeutics

@Terray_Tx

Unlocking the potential of AI-driven drug discovery with premium chemical data at unrivaled scale

◷ Joined January 2022▧ 30 Photos and videos
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Nov 16

Our collaboration with @nvidia continues to expand the frontier for Terray. With early access to cuPotential, a new CUDA-X library that speeds up molecular dynamics simulations, we realized 50% efficiency gains compared to the baseline. This allows us to generate adaptive synthetic training data on the fly at lower cost, continuously improving the accuracy of TerraBind, EMMI’s universal potency model. Thank you to our amazing collaborators at NVIDIA for their partnership. @NVIDIAHealth Read more about our work: terraytx.ai/news-and-researc…

0:12
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Nov 10

Four years in a row! 🎉 Terray has once again been named one of @biospace's Best Places to Work! At Terray we work on incredible science, and we have people who are equally incredible. People who challenge each other, share what they know, lend a hand when it's needed, and genuinely care about the people they work with and the mission to create transformative medicines for patients. This recognition is really about the community we've built together. Thank you to everyone at Terray for making it such a special place to work! #AI #DrugDiscovery #BestPlacesToWork

Post attachment
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Oct 16

With @nvidia's Nemotron 3.5 Super VL and previous versions we have embedded the ability to extract chemical synthesis routes from scientific literature. By embedding this capability directly into our EMMI platform, we are enabling our AI agents to dynamically parse and reason over chemical documents on-the-fly, and powering a continuous data flywheel that is further expanding our access to actionable chemical space and accelerating the path to novel medicines for the patients who need them. Thank you to @Nvidia and the team at @NVIDIAHealth! #AI #DrugDiscovery #HumanHealth

Big shoutout to all of our partners for making Nemotron 3.5 Super VL their own through post-training 🙌 Here’s what they’ve built 🧵

0:20
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Oct 15

Accurate extraction of chemical synthesis routes from scientific literature is critical to accelerating AI-native drug discovery workflows. Today, in collaboration with @nvidia , we are excited to announce state-of-the-art performance in extracting these routes using fine-tuned Nemotron 3.5 Super VL and Nemotron 3 Nano Omni. We are grateful to the team at @NVIDIAHealth for their partnership on this work and honored for our collaboration to be featured in today’s Nemotron 3.5 Super VL launch! By embedding this capability directly into our EMMI platform, which combines proprietary hardware, scale data, chemistry-first AI, and lab-in-the-loop automation, we are enabling our agents to dynamically parse and reason over chemical documents on-the-fly, and powering a continuous data flywheel that is further expanding our access to actionable chemical space and accelerating the path to novel medicines for the patients who need them. Read our blog: Enhanced Parsing of Chemical Reaction Diagrams terraytx.ai/news-and-researc… Read NVIDIA's blog: Nemotron 3.5 Super-VL Powers Specialized Agents with Multimodal Reasoning developer.nvidia.com/blog/nv…

Post attachment
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Oct 6

Congratulations to Narbe Mardirossian on being named to @biospace's 2026 40 Under 40 list, recognizing leaders for their innovation, impact, and commitment to improving outcomes for patients.  Over the last six years, Narbe has built the #AI and data backbone for EMMI, Terray’s integrated experimentation and chemistry-first AI platform for novel drug discovery and development.  In just one example, under his leadership, the EMMI platform has generated more than 20 billion experimentally derived binding measurements, accelerating hit identification and powering the entire drug discovery process at Terray. Congratulations Narbe!

Post attachment
NVIDIA Healthcare avatar
⟳ Terray Therapeutics retweeted
NVIDIA Healthcare@NVIDIAHealth·Sep 10

👋 Say hello to faster structure prediction NVIDIA BioNeMo Inference Runtime is in public beta. This open, PyTorch-native library speeds up biomolecular inference on NVIDIA GPUs. Optimize models including Boltz-2, OpenFold2, and Protenix v2 with specialized kernels and, where supported, CUDA Graphs - then scale with Ray-powered GPU replicas. 🙌 Huge thanks to our collaborators at @apheris_AI, @AurekaBio, @Biomap_IMI, @boltz_bio, @dataiku, @UWproteindesign, @Latent_Labs, MoleculeMind, @nebiusai, @openmsf, @open_fold, @proximabio, @SandboxAQ, @Terray_Tx, and @Xaira_Thera for partnering with us on this work. 📃 nvda.ws/46PDmlL

Post attachment
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Sep 10

Modern structure-based drug discovery heavily leverages an operation known as triangle attention. This O(n³) algorithm is a key component and the dominant cost of TerraBind, the industry’s most efficient binding affinity and structure prediction model, which we developed at Terray. We benchmarked @nvidia 's new BioNeMo Inference Runtime kernels (CuTeDSL) on our production architecture on H100 GPUs: up to 7.1x faster than standard PyTorch attention, and up to 1.8x faster than our current optimized kernel stack (cuEquivariance), with the advantage growing at the larger crop sizes that matter most for protein–ligand complexes. Integration was straightforward. We had kernels running and benchmarked within a day of getting access -- module-level swaps, no pipeline rewrites required. Congrats to the @NVIDIAHealth team on the launch! #DrugDiscovery

Post attachment
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Jul 16

Thank you Seoul! Last week Terray was fully immersed in ICML * Terray researchers Matteo Rossi and Ryan Pederson, PhD presented TerraBind, a universal cofolding-based potency model within Terray's EMMI platform that delivers 20% higher accuracy at dramatically lower compute cost unlocked by taking a fundamentally different, potency-first approach to building one of our core drug discovery models. * Terray also co-hosted an amazing evening with our friends at @NVIDIAHealth, @proximabio and @DCVC , catching up with friends and collaborators.

Post attachmentPost attachmentPost attachment
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Jun 25

Last week we shared some of our recent work on TerraSynth, a generative synthesis planner that addresses the synthesis bottleneck in small-molecule drug discovery. While generative models are good at proposing molecules with desirable properties, they often propose molecules that are difficult to synthesize in practice, slowing down DMTA cycles. TerraSynth makes synthesis planning a native part of the design loop rather than a problem to solve afterward. Integrating TerraSynth into our EMMI platform has helped us focus on the molecules that are worth making to advance our programs. Thanks to Zack and @mileswhen for their incredible work on this.

2:04
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Jun 16

We are thrilled to announce that Terray’s drug discovery platform, EMMI (Experimentation Meets Machine Intelligence), has been recognized as a World Changing Idea by Fast Company! EMMI seamlessly integrates AI and experimentation to explore the dark areas of chemical space to find and optimize novel small-molecule drugs for some of medicine’s toughest challenges. EMMI is transforming drug discovery and is changing the world! Read about EMMI terraytx.ai/news-and-researc… #DrugDiscovery #AI #FCWorldChangingIdeas

Post attachment
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Jun 16

We welcomed Lisa Decker, Chief Business Officer, to our team today! Lisa brings years of experience in building meaningful partnerships to Terray. Please join us in welcoming her! #AI #DrugDiscovery

Post attachment
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Jun 11

Today, we are excited to announce TerraSynth, the latest addition to Terray's EMMI platform. Synthesizing AI-generated molecules is a key bottleneck in modern small-molecule drug discovery. We built TerraSynth to fix that. TerraSynth is a generative synthesis planner that proposes new molecules together with a recipe for making them, keeping the DMTA cycle moving efficiently. *TerraSynth covers 67% more chemical space than the next best synthesis planner, at 1/1000th of the cost. *TerraSynth is fast to inference, and can be run directly inside the design loop, ensuring that every proposed compound has been optimized for synthesizability. *TerraSynth has prospectively reduced synthesis time for molecules synthesized at Terray by up to 75%. TerraSynth is being used in real programs at Terray every day. To read more about how we built this model and the key results, check out the blog terraytx.ai/news-and-researc…

0:08
Terray Therapeutics avatar
Terray Therapeutics@Terray_Tx·Jun 4

Terray has been built at the intersection from the moment it was founded, and we recently expanded our digital and visual footprint to reflect this. Our CEO, Jacob Berlin, PhD and CFO, Eli Berlin went into the philosophy at Terray, what makes us stand apart, and how we are bringing together experimentation and AI to transform the speed, cost, and, most importantly, success rate of small molecule drug discovery. Check out our new video about our approach and how EMMI, our platform for drug discovery and development, enables our teams to innovate. For the full blog check out the link in comments!

1:49